NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned-Reference-Cited by-同舟云学术

NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned

Published:2023-04 Issue:4 Volume:78 Page:852-865
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Rasmussen Daniel Guldager Kring,Anstee Quentin M.,Torstenson Richard,Golding Bruno,Patterson Scott D.,Brass Clifford,Thakker Paresh,Harrison Stephen^ORCID,Billin Andrew N.,Schuppan Detlef,Dufour Jean-François,Andersson Anneli^ORCID,Wigley Ioan,Shumbayawonda Elizabeth^ORCID,Dennis Andrea,Schoelch Corinna,Ratziu Vlad,Yunis Carla,Bossuyt Patrick^ORCID,Karsdal Morten Asser

Publisher

Elsevier BV

Subject

Hepatology

Reference59 articles.

1. The cost of drug development: a systematic review;Morgan;Health Policy,2011

2. Examination of clinical trial costs and barriers for drug development;Sertkaya,2014

3. R&D costs of new medicines: a landscape analysis;Simoens;Front Med,2021

4. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis;Anstee;Nat Rev Gastroenterol Hepatol,2013

5. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;J Hepatol,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review;Metabolism;2024-02

2. Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications;Frontiers in Immunology;2024-01-30

3. Isoquercitrin attenuates the progression of non-alcoholic steatohepatitis in mice by modulating galectin-3-mediated insulin resistance and lipid metabolism;Phytomedicine;2024-01

4. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease;Journal of Lipid Research;2024-01

5. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol;Contemporary Clinical Trials;2023-11